Cargando…

Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products

BACKGROUND: Recombinant factor VIII (rFVIII) products have been developed with improved pharmacokinetics, offering some patients the potential to extend dosing intervals, thereby reducing their dosing frequency while minimizing the occurrence of bleeding events. No clinical trials have been conducte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simpson, Mindy L., Desai, Vidhi, Maro, Géraldine S., Yan, Songkai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391023/ https://www.ncbi.nlm.nih.gov/pubmed/32020842 http://dx.doi.org/10.18553/jmcp.2020.19318

Ejemplares similares

A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients
por: Yan, Songkai, et al.
Publicado: (2020)

The Authors Respond
por: Simpson, Mindy L., et al.
Publicado: (2020)

Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII‐SingleChain and other common rFVIII products in Germany
por: Olivieri, Martin, et al.
Publicado: (2020)

Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
por: Jonsson, Fredrik, et al.
Publicado: (2021)

Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model
por: Tiede, Andreas, et al.
Publicado: (2020)

Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand
por: Álvarez-Román, María-Teresa, et al.
Publicado: (2023)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A
por: Batt, Katharine, et al.
Publicado: (2019)

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A
por: Di Minno, Giovanni, et al.
Publicado: (2019)

Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients
por: Abrantes, João A., et al.
Publicado: (2020)

Factor VIII replacement prophylaxis in patients with hemophilia A transitioning to adults: a systematic literature review
por: Sun, Jing, et al.
Publicado: (2021)

Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA
por: Russick, Jules, et al.
Publicado: (2020)

N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice
por: Lai, Jesse D., et al.
Publicado: (2018)

Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia A in Italy: Characteristics and Clinical Benefits
por: Schiavoni, Mario, et al.
Publicado: (2019)

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis
por: McEneny-King, Alanna, et al.
Publicado: (2017)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Recombinant porcine factor VIII: Lessons from the past and place in the management of hemophilia A with inhibitors in 2021
por: Dargaud, Yesim, et al.
Publicado: (2021)

Recombinant porcine factor VIII in acquired hemophilia A: Experience from two patients and literature review
por: Hayden, Alexander, et al.
Publicado: (2022)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis
por: Mancuso, Maria Elisa, et al.
Publicado: (2021)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

Comparison of extended to standard half-life recombinant factor VIII therapy in patients with hemophilia A on prophylactic therapy
por: McCall, Michael, et al.
Publicado: (2019)

Acquired Hemophilia A Treated with Recombinant Porcine Factor VIII: Case Report and Literature Review on Its Efficacy
por: Borro, Matteo, et al.
Publicado: (2023)

Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis
por: Croteau, Stacy E, et al.
Publicado: (2021)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy
por: Hatayama, Yuki, et al.
Publicado: (2022)

Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults
por: Konkle, Barbara A., et al.
Publicado: (2023)

Chemical Chaperones Improve Protein Secretion and Rescue Mutant Factor VIII in Mice with Hemophilia A
por: Roth, Stefanie D., et al.
Publicado: (2012)

Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study
por: Kenet, Gili, et al.
Publicado: (2021)

B cell–activating factor modulates the factor VIII immune response in hemophilia A
por: Doshi, Bhavya S., et al.
Publicado: (2021)

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
por: Krishnamoorthy, Sriram, et al.
Publicado: (2015)

Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors
por: Négrier, Claude, et al.
Publicado: (2022)

Serious bleeds in pediatric persons with hemophilia A on emicizumab prophylaxis
por: Garcia, Jessica, et al.
Publicado: (2023)

Fixed doses of N8‐GP prophylaxis maintain moderate‐to‐mild factor VIII levels in the majority of patients with severe hemophilia A
por: Chowdary, Pratima, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jfjhlcqs1l8jpoi4uuu28j9a6r